Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2022-12-29 |
2022-09 |
0 |
N/A |
N/A |
N/A |
2022-10-06 |
2022-06 |
0 |
N/A |
N/A |
N/A |
2022-06-30 |
2022-03 |
-0.16 |
N/A |
N/A |
N/A |
2022-03-10 |
2021-12 |
-0.18 |
N/A |
N/A |
N/A |
2021-10-28 |
2021-09 |
-0.2 |
N/A |
N/A |
N/A |
2021-07-29 |
2021-06 |
-0.18 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2022-04-29 |
HC Wainwright & Co. |
Downgrade |
Buy |
Neutral |
2022-04-29 |
Stifel |
Downgrade |
Buy |
Hold |
2021-04-06 |
SVB Leerink |
Upgrade |
|
Outperform |
2021-02-11 |
Needham |
Upgrade |
|
Buy |
2020-11-25 |
Needham |
Upgrade |
|
Buy |
2020-11-25 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2022-05-24 |
BASKETT FOREST |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Sale |
2022-05-24 |
BEHBAHANI ALI |
Director and Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Sale |
2022-06-01 |
CLARK WILLIAM D |
Chief Executive Officer |
304.38K |
Sale |
2022-06-01 |
DUVALL DIANTHA |
Chief Financial Officer |
75.39K |
Sale |
2022-06-01 |
FLECHTNER JESSICA BAKER |
Officer |
89.03K |
Sale |
2022-05-24 |
FLORENCE ANTHONY A JR |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2022-03-30 |
NEA Management Company, LLC |
10.38M |
155.65K |
17.65% |
2022-03-30 |
Avoro Capital Advisors LLC |
5.08M |
76.26K |
8.65% |
2022-03-30 |
BVF Inc. |
4.01M |
60.19K |
6.83% |
2022-03-30 |
Commodore Capital, LP |
3.08M |
46.20K |
5.24% |
2022-03-30 |
Point72 Asset Management, L.P. |
2.58M |
38.65K |
4.38% |
2022-03-30 |
Kingdon Capital Management LLC |
1.97M |
29.58K |
3.35% |
Report Date |
Organization |
Position |
Value |
Percentage |
2022-03-30 |
Vanguard Total Stock Market Index Fund |
1.21M |
18.22K |
2.07% |
2022-03-30 |
Vanguard Extended Market Index Fund |
279.64K |
4.19K |
0.48% |
2022-04-29 |
Fidelity Extended Market Index Fund |
184.92K |
2.77K |
0.31% |
2022-04-29 |
iShares Core S&P Total U.S. Stock Market ETF |
106.06K |
1.59K |
0.18% |
2022-05-30 |
iShares Micro Cap ETF |
95.32K |
1.43K |
0.16% |
2022-03-30 |
Vanguard Institutional Index-Inst Total Stock Market Ind |
47.39K |
710.00 |
0.08% |
Split |
Date |
1 : 8 |
2019-05-22 |